Pages that link to "Q44990224"
Jump to navigation
Jump to search
The following pages link to Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy (Q44990224):
Displaying 50 items.
- Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism (Q24603957) (← links)
- Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease (Q26745946) (← links)
- The metabolic syndrome (Q29616309) (← links)
- Simvastatin: a review (Q34372227) (← links)
- Understanding and preventing drug-drug and drug-gene interactions (Q34415944) (← links)
- Diagnostic evaluation of rhabdomyolysis (Q35624916) (← links)
- Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes (Q35855311) (← links)
- The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus (Q35871965) (← links)
- PPAR ligands: potential therapies for metabolic syndrome (Q36016948) (← links)
- Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions (Q36349758) (← links)
- Fibrates in combination with statins in the management of dyslipidemia (Q36366283) (← links)
- Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly (Q36475343) (← links)
- Managing cardiovascular risk in patients with metabolic syndrome (Q36563115) (← links)
- Can pharmacogenetics help rescue drugs withdrawn from the market? (Q36596713) (← links)
- Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia (Q36758082) (← links)
- Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia (Q36802569) (← links)
- Atorvastatin: a safety and tolerability profile (Q36957813) (← links)
- Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing (Q37019924) (← links)
- New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process (Q37124261) (← links)
- A neuromuscular approach to statin-related myotoxicity. (Q37124768) (← links)
- Simvastatin: two decades in a circle (Q37165690) (← links)
- Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors (Q37473376) (← links)
- Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network (Q37473382) (← links)
- OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis (Q37489569) (← links)
- Myopathy with statin-fibrate combination therapy: clinical considerations (Q37563958) (← links)
- Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study (Q37663503) (← links)
- Atorvastatin: safety and tolerability (Q37765562) (← links)
- Statin Myopathy: Significant Problem With Minimal Awareness by Clinicians and no Emphasis by Clinical Investigators (Q37855316) (← links)
- Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins (Q37855801) (← links)
- Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population (Q37932168) (← links)
- Statin-induced myopathies (Q37946182) (← links)
- Atorvastatin calcium plus amlodipine for the treatment of hypertension. (Q38058827) (← links)
- Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. (Q38109095) (← links)
- A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs (Q38113494) (← links)
- Muscle- and skeletal-related side-effects of statins: tip of the iceberg? (Q38250622) (← links)
- Drug-drug interactions that interfere with statin metabolism (Q38522299) (← links)
- Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions (Q38684505) (← links)
- Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients (Q38723259) (← links)
- Gemfibrozil in Combination with Statins-Is It Really Contraindicated? (Q38756974) (← links)
- The Potential Return on Public Investment in Detecting Adverse Drug Effects (Q40201233) (← links)
- Commentary: The Growing Role of Epidemiology in Drug Safety Regulation (Q44843585) (← links)
- Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. (Q44899027) (← links)
- Dangers of rosuvastatin identified before and after FDA approval (Q44953775) (← links)
- Myopathies under therapy with lipid-lowering agents (Q45194187) (← links)
- Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions (Q45828266) (← links)
- Elevated creatine phosphokinase levels associated with linezolid therapy. (Q45982016) (← links)
- Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors (Q46536200) (← links)
- Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation (Q47133234) (← links)
- Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. (Q48347873) (← links)
- Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. (Q48792346) (← links)